(TRIAL COMMENCING SHORTLY) This international clinical trial, estimated to commence on 8 May 2020, is in partnership with UCSD University of California San Diego and local hospitals. 200 COVID-19 positive patients in Stockholm and California will be receiving HBOT treatment. Inclusion criteria: patients with acute lung injury and Acute Respiratory Distress Syndrome (ARDS) and needing intubation, ventilator-assistance or ECMO-assisted treatment within 7 days of admission to hospital; plus at least one factor for increased mortality in COVID-19 i.e. smoking, hypertension, diabetes, cardiovascular disease. Participants are randomized into an HBOT treatment group vs a non-HBOT control group.
Trial duration is 30 days and measures the physiological anti-inflammatory effects of HBOT to treat COVID-19 patients with ARDS. Outcome measures for comparison include oxygen requirement, blood work markers, changes in pulmonary CT scans and chest x-rays/ultrasound, mechanical ventilation requirement, ICU duration and mortality statistics.